A lawyer for healthcare activists says India's Supreme Court has rejected drug maker Novartis AG's right to patent a new version of a lifesaving cancer drug.
The landmark ruling Monday is a victory for India's $26 billion generic drug industry that provides cheap medicines to millions around the world.
The ruling is a precedent that prevents international pharmaceutical companies from obtaining fresh patents in India on updated versions of existing drugs.
Lawyer Anand Grover said such a ruling would help poor people get access to affordable, generic versions of lifesaving medicines.
Novartis has fought a legal battle in India since 2006 for a fresh patent for a leukemia drug.
India's patent office had rejected the company's patent application because it was not a new medicine.